NIH invests in next iteration of public-private partnership to advance precision medicine research for Alzheimer’s disease
NIH Office of Communications and Public Liaison, NIH News Media Branch, 301-496-5787, firstname.lastname@example.org
NIA Press Team, 301-496-1752, NIAPressTeam@mail.nih.gov
Effort is part of the Accelerating Medicines Partnership to enable development of effective targeted therapies.
The National Institutes of Health has launched the next version of the Accelerating Medicines Partnership (AMP) Alzheimer’s disease program (AMP AD 2.0) to expand the open science, big data approach for identifying biological targets for therapeutic intervention. AMP AD 2.0 is supporting new technologies, including cutting-edge, single-cell profiling, and computational modeling, to enable a precision medicine approach to therapy development. Managed through the Foundation for the NIH (FNIH), AMP AD 2.0 brings together NIH, industry, nonprofit and other organizations with a shared goal of using open science practices to accelerate the discovery of new drug targets, biomarkers, and disease subtypes.
“Unraveling the complex biological mechanisms that cause Alzheimer’s disease is critical for therapeutic development,” said NIH Director Francis S. Collins, M.D., Ph.D. “AMP AD 2.0 aims to add greater precision to the molecular maps developed in the first iteration of this program. This will identify biological targets and biomarkers to inform new therapeutic interventions for specific disease subtypes.”
Alzheimer’s, the most common cause of dementia, affects an estimated 5.8 million Americans 65 and older. Because the prevalence of this disease is greater among Black and Latino Americans than among white Americans, AMP AD 2.0 will expand the molecular characterization of Alzheimer’s in brain, blood, and spinal fluid samples collected in these diverse populations. These datasets will allow the AMP AD 2.0 research teams to refine the characterization of new targets, discover new fluid biomarkers, define disease subtypes, and increase the understanding of causative factors and steps in disease progression. The knowledge gained will inform the development of therapies that can be tailored to different stages of the disease and diverse disease risk profiles.
“AMP AD has helped transform the way we learn about the disease process and identify new targets for treatment,” said Richard J. Hodes, M.D., director of the National Institute on Aging (NIA), part of NIH. “By expanding the molecular characterization of Alzheimer’s disease to be more inclusive of diverse populations and by renewing the commitment to open science practices for sharing data, methods, and results, we will enable researchers across the globe to better understand the complex nature of the disease and take a precision medicine approach to the development of effective treatments.”
During the first AMP Alzheimer’s program, research teams generated a wealth of high-quality data from human biological samples and animal and cell-based models and discovered more than 500 unique candidate targets through unbiased computational methods. These novel data resources were made available through a centralized data infrastructure and data-sharing platform, the AD Knowledge Portal, and the portal-linked, open-source platform Agora. The wide availability of this data has led to many new insights on the role of the genome, proteome, metabolome, and microbiome in the disease process. To date, more than 3,000 researchers around the world, representing academic, biotechnology, and pharmaceutical industry sectors, have used these data resources for research on Alzheimer’s and related dementias.
NIA will lead research efforts and contribute an estimated total of $61.4 million over five years, pending availability of funds. This includes funding for a data coordinating center at Sage Bionetworks, and six multi-institutional, cross-disciplinary academic research teams.
AMP AD 2.0 private funding partners include Eisai Inc., Gates Ventures, and Takeda Pharmaceutical Company Limited. The Alzheimer’s Association and GlaxoSmithKline plc (GSK), who have been partners since the beginning of the AMP Alzheimer’s program, will again participate and continue to provide support towards the program’s goals. The total co-funding contribution from all private partners will be approximately $13.45 million, which will be managed through FNIH.
As before, FNIH will manage a steering committee to provide strategic direction of the partnership’s research plans with representation from public- and private-sector partners. FNIH’s steering committee management will be directed by an AMP AD executive committee made up of leaders from NIA, industry, the U.S. Food and Drug Administration, and not-for-profit research, advocacy, and care organizations.
“This partnership offers real hope to the tens of millions of people affected by Alzheimer’s disease,” said Maria C. Freire, Ph.D., president and executive director of the FNIH. “Collaboration through the first round of AMP AD has already enabled breakthrough advances in researchers’ understanding of how Alzheimer’s disease progresses, uncovering numerous potential targets for drug therapy in a field where treatment options are severely limited.”
AMP AD 2.0 is funded by NIH grants U01AG046139, U01AG046170, U01AG061357, U01AG061359, U01AG061835, U01AG061356, and U24AG061340. NIA leads NIH’s strategic planning, development and implementation of research milestones associated with the research goal of the National Plan to Address Alzheimer’s and Related Dementias, to effectively treat and prevent Alzheimer’s and related dementias by 2025. The research supported by the AMP AD 2.0 partnership will contribute to the goals of several strategic milestones, related to precision medicine research and the discovery and validation of novel targets and fluid biomarkers.
About the Foundation for the National Institutes of Health: The Foundation for the National Institutes of Health creates and manages alliances with public and private institutions in support of the mission of the NIH, the world’s premier medical research agency. The Foundation, also known as the FNIH, works with its partners to accelerate biomedical research and strategies against diseases and health concerns in the United States and across the globe. The FNIH organizes and administers research projects; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health issues. Established by Congress in 1990, the FNIH is a not-for-profit 501(c)(3) charitable organization. For additional information about the FNIH, please visit fnih.org.
About the National Institute on Aging (NIA): NIA leads the U.S. federal government effort to conduct and support research on aging and the health and well-being of older people. Learn more about age-related cognitive change and neurodegenerative diseases via NIA’s Alzheimer's and related Dementias Education and Referral (ADEAR) Center website. Visit the main NIA website for information about a range of aging topics, in English and Spanish, and stay connected.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health®